Merck reportedly initiated a global Phase 3 study of OHTUVAYRE in patients with COPD. The company was also set to present new HIV treatment and prevention data at a conference running November 8–11, 2026. The FDA set an April 22, 2027 target action date for two supplemental IDVYNSO applications.
Key facts
Merck is set to present new HIV treatment and prevention data at a conference from November 8 to 11, 2026. source
Merck initiated a global Phase 3 study of OHTUVAYRE in patients with COPD. source